Mayne Pharma (MYX.AX) rises after settling IMVEXXY patent litigation with Sun Pharma
Mayne Pharma shares rose up to 2.1% after it agreed to settle US patent litigation with India’s Sun Pharma over IMVEXXY and FDA Orange Book patents, with an agreed pathway for a potential generic entry on Oct 21, 2032, or earlier under certain circumstances.